Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call.
Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®Nine month year to date 2023 revenues increased 9% to US$164.1 million, compared to nine month year to date 2022RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to the second quart
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans,...
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being...